Clinical trial
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
NCT02829814 is registered in ClinicalTrials.gov with Tonix Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- July 22, 2016
- Completion date
- September 13, 2016
- Enrollment
- 51 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.